Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of $78.84 million. The enterprise value is -$37.83 million.
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellectis has 100.71 million shares outstanding. The number of shares has increased by 0.31% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 100.71M |
| Shares Change (YoY) | +0.31% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 2.12% |
| Owned by Institutions (%) | 16.05% |
| Float | 48.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.46 |
| Forward PS | 0.54 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15
| Current Ratio | 1.15 |
| Quick Ratio | 1.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.24 |
Financial Efficiency
Return on equity (ROE) is -307.50% and return on invested capital (ROIC) is -78.17%.
| Return on Equity (ROE) | -307.50% |
| Return on Assets (ROA) | -27.75% |
| Return on Invested Capital (ROIC) | -78.17% |
| Return on Capital Employed (ROCE) | -171.33% |
| Weighted Average Cost of Capital (WACC) | 21.49% |
| Revenue Per Employee | $140,166 |
| Profits Per Employee | -$556,227 |
| Employee Count | 229 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -321,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.12% in the last 52 weeks. The beta is 2.94, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 2.94 |
| 52-Week Price Change | -75.12% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 2.88 |
| Relative Strength Index (RSI) | 41.90 |
| Average Volume (20 Days) | 67,407 |
Short Selling Information
The latest short interest is 333,012, so 0.60% of the outstanding shares have been sold short.
| Short Interest | 333,012 |
| Short Previous Month | 320,614 |
| Short % of Shares Out | 0.60% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.16 |
Income Statement
In the last 12 months, Cellectis had revenue of $32.10 million and -$127.38 million in losses. Loss per share was -$1.22.
| Revenue | 32.10M |
| Gross Profit | 32.10M |
| Operating Income | -123.55M |
| Pretax Income | -127.70M |
| Net Income | -127.38M |
| EBITDA | -112.13M |
| EBIT | -123.55M |
| Loss Per Share | -$1.22 |
Full Income Statement Balance Sheet
The company has $146.71 million in cash and $25.88 million in debt, with a net cash position of $120.82 million or $1.20 per share.
| Cash & Cash Equivalents | 146.71M |
| Total Debt | 25.88M |
| Net Cash | 120.82M |
| Net Cash Per Share | $1.20 |
| Equity (Book Value) | -17.63M |
| Book Value Per Share | -0.18 |
| Working Capital | 21.89M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$41.63 million and capital expenditures -$2.18 million, giving a free cash flow of -$43.80 million.
| Operating Cash Flow | -41.63M |
| Capital Expenditures | -2.18M |
| Depreciation & Amortization | 11.43M |
| Net Borrowing | -16.36M |
| Free Cash Flow | -43.80M |
| FCF Per Share | -$0.43 |
Full Cash Flow Statement Margins
| Gross Margin | 100.00% |
| Operating Margin | -384.93% |
| Pretax Margin | -397.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.31% |
| Shareholder Yield | -0.31% |
| Earnings Yield | -118.74% |
| FCF Yield | -55.56% |
Analyst Forecast
The average price target for Cellectis is $4.45, which is 332.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.45 |
| Price Target Difference | 332.04% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -20.99% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |